PTC: Update to the U.S. Duchenne Community on the Ataluren (Translarna) NDA Review

On August 11, 2025, PTC Therapeutics shared a community update about the status of the Ataluren FDA filing, the first potential therapy specifically for individuals with nonsense mutation Duchenne.

To view their community update, please click here.